| 1.1101 -0.04 (-3.47%) | 01-09 13:18 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.46 |
1-year : | 1.7 |
| Resists | First : | 1.25 |
Second : | 1.46 |
| Pivot price | 0.93 |
|||
| Supports | First : | 0.96 |
Second : | 0.79 |
| MAs | MA(5) : | 1.05 |
MA(20) : | 0.93 |
| MA(100) : | 1.04 |
MA(250) : | 1.11  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 82.5 |
| RSI | RSI(14): 66.6 |
|||
| 52-week | High : | 1.69 | Low : | 0.7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RNXT ] has closed Bollinger Bands are 20.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.2 - 1.21 | 1.21 - 1.21 |
| Low: | 1.04 - 1.04 | 1.04 - 1.05 |
| Close: | 1.14 - 1.15 | 1.15 - 1.16 |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Thu, 08 Jan 2026
New study aims to make pancreatic cancer chemo hit tumors, not the whole body - Stock Titan
Fri, 02 Jan 2026
RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Mon, 22 Dec 2025
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 - Investing.com
Mon, 08 Dec 2025
Agah Ramtin, RenovoRx chief medical officer, buys $9,600 in RNXT - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 3.276e+007 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 676 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 202.9 % |
| Return on Equity (ttm) | -68.4 % |
| Qtrly Rev. Growth | 928000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -113.66 |
| EBITDA (p.s.) | 487597 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 6.68 |
| Dividend | 0 |
| Forward Dividend | 443580 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|